| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
| Targets |
WDR5-IN-6 targets the WDR5-binding motif (WBM) site of the WD repeat domain 5 (WDR5) protein. WDR5 is a scaffolding protein that plays a critical role in chromatin remodeling and gene transcription. It is a component of the MLL (mixed-lineage leukemia) complex and is essential for the methylation of histone H3 on lysine 4 (H3K4). By targeting the WBM site, WDR5-IN-6 disrupts the interaction between WDR5 and its binding partners.
|
|---|---|
| ln Vitro |
WDR5-IN-6 (compound 19) has an EC50 value of 14.89 μM and suppresses the proliferation of IMR32 and LAN5 cells, respectively. At 20 μM, it exhibits no effect on HEK293T cells and a moderate inhibitory effect on SK-N-AS cells [1].
In vitro, WDR5-IN-6 inhibits cell proliferation of neuroblastoma cell lines with potent anti-tumor activity. It is a selective inhibitor of WDR5 and is highly synergistic with OICR-9429, a WDR5 inhibitor targeting the WIN site. These in vitro activities support its use in studying the role of WDR5 in cancer, particularly neuroblastoma. |
| ln Vivo |
In vivo data for WDR5-IN-6 is not extensively reported in publicly available sources. As a potent WDR5 inhibitor with anti-tumor activity in neuroblastoma cell lines, the compound has potential applications in animal models of neuroblastoma and other cancers. However, specific published in vivo efficacy studies are not detailed in the current literature. WDR5-IN-6 is primarily used as a research tool for studying WDR5 biology.
|
| Enzyme Assay |
The in vitro WDR5 binding assay for WDR5-IN-6 is conducted using recombinant WDR5 protein. The compound's binding affinity for the WBM site is measured using techniques such as surface plasmon resonance (SPR) or fluorescence polarization. The compound is added at various concentrations, and the binding affinity (Kd) is calculated. The selectivity for the WBM site over the WIN site is confirmed by competitive binding assays.
|
| Cell Assay |
Cellular assays for WDR5-IN-6 are conducted in neuroblastoma cell lines. Cells are treated with varying concentrations of the compound. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. The compound's effects on cell cycle progression and apoptosis are assessed by flow cytometry. The synergy with OICR-9429 is evaluated by combining the two compounds and measuring the combination index.
|
| Animal Protocol |
In vivo studies for WDR5-IN-6 would typically involve xenograft mouse models of neuroblastoma. The compound would be administered via oral or intraperitoneal routes. Efficacy would be assessed by measuring tumor growth inhibition. Pharmacodynamic markers such as WDR5 target engagement and changes in gene expression would be evaluated in tumor tissues. However, specific published in vivo protocols for WDR5-IN-6 are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for WDR5-IN-6 is not extensively reported in publicly available sources. The compound has a molecular weight of 327.19 and a molecular formula of C13H8Cl2N2O2S. It has a CAS number of 326901-92-2. As a small molecule, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available.
|
| Toxicity/Toxicokinetics |
Toxicity data for WDR5-IN-6 is limited. As with all research compounds, WDR5-IN-6 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References | |
| Additional Infomation |
WDR5-IN-6 (CAS 326901-92-2) is a selective inhibitor of WDR5 that targets the WBM site. It exhibits potent antitumor activity and inhibits cell proliferation in neuroblastoma cell lines. It is highly synergistic with OICR-9429, a WIN-site inhibitor. WDR5-IN-6 has a molecular formula of C13H8Cl2N2O2S and a molecular weight of 327.19. It is for research use only.
|
| Molecular Formula |
C13H8N2O2SCL2
|
|---|---|
| Molecular Weight |
327.186
|
| Exact Mass |
325.97
|
| CAS # |
326901-92-2
|
| PubChem CID |
684718
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
454
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC(Cl)=C(S(N2C=NC3=CC=CC=C23)(=O)=O)C=1
|
| InChi Key |
PXUHMEZESKEPKJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H8Cl2N2O2S/c14-9-5-6-10(15)13(7-9)20(18,19)17-8-16-11-3-1-2-4-12(11)17/h1-8H
|
| Chemical Name |
1-(2,5-dichlorophenyl)sulfonylbenzimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0563 mL | 15.2816 mL | 30.5633 mL | |
| 5 mM | 0.6113 mL | 3.0563 mL | 6.1127 mL | |
| 10 mM | 0.3056 mL | 1.5282 mL | 3.0563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
